BERLIN (Reuters) – German pharmaceutical giant Bayer is investigating whether CureVac can help it implement its COVID-19 experimental vaccine, its boss reportedly said Sunday.
Although inclusion campaigns have begun around the world using various COVID-19 vaccines, many countries say the ability to shoot into arms is limited by lower-than-expected supply. due to production shortages.
“We are willing to make every effort to pull this off,” Werner Baumann told the Welt newspaper on Sunday.
“This is not just about financial issues but about getting the vaccine out as soon as possible. ”
Bayer agreed this month to assist the German subsidiary CureVac in developing its COVID-19 vaccine candidate, which is in late-stage clinical trials and has not yet been approved.
Baumann said the drug dealer was “intensively investigating” whether to expand its cooperation to include the manufacture of the vaccine for CureVac.
“With our production network in Germany and the US and the corresponding lead time, we would in principle be able to produce vaccines in larger quantities,” he said.
On Friday U.S. drugmaker Pfizer said there would be a temporary slowdown in the vaccine it developed with German partner BioNTech, announcing changes in manufacturing processes to boost production.
Reciting with Caroline Copley; Edited by David Goodman